I Roots, G Laschinski, F Arjomand-Nahad, J Kirchheiner, D Schwarz, J Brockmöller, I Cascorbi, T Gerloff
{"title":"药物代谢的基因型与表型关系。","authors":"I Roots, G Laschinski, F Arjomand-Nahad, J Kirchheiner, D Schwarz, J Brockmöller, I Cascorbi, T Gerloff","doi":"10.1007/978-3-540-49529-1_6","DOIUrl":null,"url":null,"abstract":"<p><p>Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Today, the relationships between dosage requirements and genetic variations in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C19 or in drug transporters such as p-glycoprotein (ABCB1) and OATP-C (SLC21A6) are substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better because of higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. In some cases, genetic tests can help distinguish between responders and nonresponders of a specific drug treatment, and genotype-based dosage is possible.</p>","PeriodicalId":80277,"journal":{"name":"Ernst Schering Research Foundation workshop","volume":" 59","pages":"81-100"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-540-49529-1_6","citationCount":"7","resultStr":"{\"title\":\"Genotype and phenotype relationship in drug metabolism.\",\"authors\":\"I Roots, G Laschinski, F Arjomand-Nahad, J Kirchheiner, D Schwarz, J Brockmöller, I Cascorbi, T Gerloff\",\"doi\":\"10.1007/978-3-540-49529-1_6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Today, the relationships between dosage requirements and genetic variations in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C19 or in drug transporters such as p-glycoprotein (ABCB1) and OATP-C (SLC21A6) are substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better because of higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. In some cases, genetic tests can help distinguish between responders and nonresponders of a specific drug treatment, and genotype-based dosage is possible.</p>\",\"PeriodicalId\":80277,\"journal\":{\"name\":\"Ernst Schering Research Foundation workshop\",\"volume\":\" 59\",\"pages\":\"81-100\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/978-3-540-49529-1_6\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ernst Schering Research Foundation workshop\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/978-3-540-49529-1_6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ernst Schering Research Foundation workshop","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-540-49529-1_6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
摘要
药物遗传学是临床药理学的一个领域,研究遗传因素如何影响药物反应。如果在开始药物治疗之前适当地考虑到遗传特征,药物的类型和剂量可以根据个体患者的需要进行调整。目前,药物代谢酶如细胞色素P450 (CYP) 2D6、CYP2C9和CYP2C19或p-糖蛋白(ABCB1)和ooatp - c (SLC21A6)等药物转运体的剂量需求与遗传变异之间的关系得到了最好的证实。如果酶活性缺乏或微弱,标准剂量会带来比平时更多的副作用。然而,有时,由于浓度较高,治疗效果可能会更好:用于根除幽门螺杆菌的质子泵抑制剂在CYP2C19变异缺陷携带者中更有效。在某些情况下,基因测试可以帮助区分特定药物治疗的应答者和无应答者,并且基于基因型的剂量是可能的。
Genotype and phenotype relationship in drug metabolism.
Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Today, the relationships between dosage requirements and genetic variations in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C19 or in drug transporters such as p-glycoprotein (ABCB1) and OATP-C (SLC21A6) are substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better because of higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. In some cases, genetic tests can help distinguish between responders and nonresponders of a specific drug treatment, and genotype-based dosage is possible.